Patents by Inventor Jonathan D. Benson

Jonathan D. Benson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10927373
    Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: February 23, 2021
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
  • Publication number: 20190211333
    Abstract: Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds, that are useful in directing the compounds to the target in vivo. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to an expression-inhibiting oligomeric compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.
    Type: Application
    Filed: March 25, 2019
    Publication date: July 11, 2019
    Inventors: David B. Rozema, Darren H. Wakefield, Andrei V. Blokhin, Jonathan D. Benson, Zhen Li, Tao Pei, Fred Fleitz
  • Patent number: 10246709
    Abstract: Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds, that are useful in directing the compounds to the target in vivo. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to an expression-inhibiting oligomeric compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: April 2, 2019
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, Andrei V. Blokhin, Jonathan D. Benson, Zhen Li, Tao Pei, Fred Fleitz
  • Patent number: 10059681
    Abstract: We describe anhydride compounds suitable for physiologically labile modification of amine-containing molecules. The described anhydrides form reversible linkages having desirable kinetics for in vivo delivery of biologically active molecules. Also described are endosomolytic polymers formed by modification of membrane active polyamines with the described anhydrides.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: August 28, 2018
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Andrei V. Blokhin, David B. Rozema, Jonathan D. Benson, Jeffrey C. Carlson
  • Publication number: 20180230470
    Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.
    Type: Application
    Filed: April 16, 2018
    Publication date: August 16, 2018
    Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
  • Patent number: 10047361
    Abstract: Described are improved disulfide-containing alkyne linking agents having have branched disulfides. The improved linking agents exhibit improved stability. The linking agents are useful for attachment of oligonucleotides to targeting groups or delivery agents.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: August 14, 2018
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Aaron Almeida, Andrei V. Blokhin, Darren H. Wakefield, Jonathan D. Benson, David B. Rozema
  • Patent number: 9976141
    Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: May 22, 2018
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
  • Publication number: 20180023084
    Abstract: Described are improved disulfide-containing alkyne linking agents having have branched disulfides. The improved linking agents exhibit improved stability. The linking agents are useful for attachment of oligonucleotides to targeting groups or delivery agents.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 25, 2018
    Inventors: Aaron Almeida, Andrei V. Blokhin, Darren H. Wakefield, Jonathan D. Benson, David B. Rozema
  • Patent number: 9803201
    Abstract: Described are improved disulfide-containing alkyne linking agents having have branched disulfides. The improved linking agents exhibit improved stability. The linking agents are useful for attachment of oligonucleotides to targeting groups or delivery agents.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: October 31, 2017
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Aaron Almeida, Andrei V. Blokhin, Darren H. Wakefield, Jonathan D. Benson, David B. Rozema
  • Publication number: 20170253875
    Abstract: Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds, that are useful in directing the compounds to the target in vivo. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to an expression-inhibiting oligomeric compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.
    Type: Application
    Filed: March 7, 2017
    Publication date: September 7, 2017
    Inventors: David B. Rozema, Darren H. Wakefield, Andrei V. Blokhin, Jonathan D. Benson, Zhen Li, Tao Pei, Fred Fleitz
  • Publication number: 20160348107
    Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 1, 2016
    Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
  • Patent number: 9481661
    Abstract: We describe anhydride compounds suitable for physiologically labile modification of amine-containing molecules. The described anhydrides form reversible linkages having desirable kinetics for in vivo delivery of biologically active molecules. Also described are endosomolytic polymers formed by modification of membrane active polyamines with the described anhydrides.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: November 1, 2016
    Assignee: Arrowhead Madison, Inc.
    Inventors: Andrei V Blokhin, David B Rozema, Jonathan D Benson, Jeffrey C Carlson
  • Publication number: 20160272971
    Abstract: Described are improved disulfide-containing alkyne linking agents having have branched disulfides. The improved linking agents exhibit improved stability. The linking agents are useful for attachment of oligonucleotides to targeting groups or delivery agents.
    Type: Application
    Filed: March 16, 2016
    Publication date: September 22, 2016
    Inventors: Aaron Almeida, Andrei V. Blokhin, Darren H. Wakefield, Jonathan D. Benson, David B. Rozema
  • Publication number: 20160272605
    Abstract: We describe anhydride compounds suitable for physiologically labile modification of amine-containing molecules. The described anhydrides form reversible linkages having desirable kinetics for in vivo delivery of biologically active molecules. Also described are endosomolytic polymers formed by modification of membrane active polyamines with the described anhydrides.
    Type: Application
    Filed: May 27, 2016
    Publication date: September 22, 2016
    Inventors: Andrei V. Blokhin, David B. Rozema, Jonathan D. Benson, Jeffrey C. Carlson
  • Patent number: 9107957
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: August 18, 2015
    Assignee: Arrowhead Madison Inc.
    Inventors: David B Rozema, David L Lewis, Darren Wakefield, Eric Kitas, Philipp Hadwiger, Jon Wolff, Ingo Röhl, Peter Mohr, Torsten Hoffmann, Kerstin Jahn-Hofmann, Hans Martin Mueller, Günther Ott, Andrei V Blokhin, Jonathan D Benson, Jeffrey C Carlson
  • Patent number: 8802773
    Abstract: The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 12, 2014
    Assignee: Arrowhead Madison Inc.
    Inventors: David B Rozema, David L Lewis, Darren H Wakefield, Eric A Kitas, Philipp Hadwiger, Jon A Wolff, Ingo Roehl, Peter Mohr, Torsten Hoffmann, Kerstin Jahn-Hofmann, Hans Martin Mueller, Guenther Ott, Andrei V Blokhin, Jeffrey C Carlson, Jonathan D Benson
  • Publication number: 20140128584
    Abstract: We describe anhydride compounds suitable for physiologically labile modification of amine-containing molecules. The described anhydrides form reversible linkages having desirable kinetics for in vivo delivery of biologically active molecules. Also described are endosomolytic polymers formed by modification of membrane active polyamines with the described anhydrides.
    Type: Application
    Filed: May 31, 2012
    Publication date: May 8, 2014
    Applicant: ARROWHEAD MADISON INC.
    Inventors: Andrei V. Blokhin, David B. Rozema, Jonathan D. Benson, Jeffrey C. Carlson
  • Publication number: 20130281658
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.
    Type: Application
    Filed: June 25, 2013
    Publication date: October 24, 2013
    Inventors: David B Rozema, David L Lewis, Darren Wakefield, Eric Kitas, Philipp Hadwiger, Jon Wolff, Ingo Röhl, Peter Mohr, Torsten Hoffmann, Kerstin Jahn-Hofmann, Hans Martin Mueller, Günther Ott, Andrei V Blokhin, Jonathan D Benson, Jeffrey C Carlson
  • Patent number: 8501930
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: August 6, 2013
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, David L. Lewis, Jon A. Wolff, Andrei V. Blokhin, Jonathan D. Benson, Jeffrey C. Carlson, Philipp Hadwiger, Eric A. Kitas, Torsten Hoffmann, Kerstin Jahn-Hofmann, Peter Mohr, Hans Martin Mueller, Guenther Ott, Ingo Roehl
  • Patent number: 8426554
    Abstract: The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: April 23, 2013
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, David L. Lewis, Jon A. Wolff, Andrei V. Blokhin, Jonathan D. Benson, Jeffrey C. Carlson, Philipp Hadwiger, Eric A. Kitas, Torsten Hoffmann, Kerstin Jahn-Hoffmann, Peter Mohr, Hans Martin Mueller, Guenther Ott, Ingo Roehl